StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for PMCB yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $0.80 | $0.76 | -5.53% | 0.2M |
| 05-19 | $0.78 | $0.73 | -6.12% | 0.2M |
| 05-20 | $0.75 | $0.77 | +2.43% | 0.2M |
| 05-21 | $0.78 | $0.80 | +2.05% | 0.3M |
| 05-22 | $0.79 | $0.81 | +3.12% | 0.6M |
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-01-31 | Q4 2025 2025-10-31 | Q3 2025 2025-07-31 | Annual 2025 2025-04-30 |
|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
Operating Income | $-4.34M | $-2.22M | $-848.30K | $-4.38M |
Net Income | $-15.03M | $-7.42M | $-8.36M | $30.66M |
EPS (Diluted) | $-2.41 | $-2.47 | $-1.23 | $3.19 |
Total Assets | $55.87M | $55.98M | $45.11M | $55.17M |
Total Liabilities | $16.47M | $19.42M | $1.52M | $3.28M |
Cash & Equivalents | $20.17M | $15.41M | $13.18M | $15.17M |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | 10.74M | 6.80M | 6.80M | 6.80M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.